ANVS - Rasio kapitalisasi pasar marang pendapatan Annovis Bio Inc
The revenue multiple reflects the high reputation of Annovis Bio, Inc. (ANVS) within the scientific community due to its dementia research, with this metric currently standing at . The company adheres to environmental standards by implementing energy conservation and waste filtration in its laboratories. Business efficiency is being enhanced through AI models and robotics, which automate the discovery of new drug formulas.
Annovis Bio, Inc. (ANVS) - rincian metrik lan laporan keuangan
- rega lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Annovis Bio, Inc.|ANVS - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Annovis Bio, Inc.|ANVS - Gunggung utang perusahaan|Utang-utang marang aset resik Annovis Bio|ANVS - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Annovis Bio|Indikator likuiditas cepet annovisbio.com
- rincian asil keuangan lan kelipatan valuasi:
ANVS - Penghasilan resik|Prakiraan bathi perusahaan Annovis Bio, Inc.|ANVS - Pangali P/E|Pangali Forward P/E Annovis Bio Corporation|ANVS - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Annovis Bio, Inc.|ANVS - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Annovis Bio|ANVS - Bathi saben saham sajrone rolas wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan annovisbio.com|ANVS - Wutah bathi saben saham ing taun lumaku|Proyeksi kacepetan wutah bathi saben saham kanggo taun ngarep Annovis Bio, Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:ANVS, Annovis Bio Inc
Assessing the margin of safety for Annovis Bio, Inc. (ANVS) requires an analysis of the ratio of market capitalization to annual revenue. This coefficient measures the premium investors are willing to pay for every dollar of sales, reflecting current market expectations. Monitoring the company's P/S ratio allows for the identification of overpayment risks or asset undervaluation. High values here are justified by the uniqueness of buntianepide and the potential for pricing power within the neurodegeneration treatment segment.
Pesaing Annovis Bio, Inc.
BIIB (Biogen) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NBIX (Neurocrine Corp)|Regencell Bioscience - Rasio rega marang pendapatan|Axsome Therapeutics - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Rasio rega marang pendapatan|Rega marang dodolan Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator P/S|CPRX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S DNLI|Koefisien rega marang pendapatan Harmony Biosciences|Biohaven Ltd - Kapitalisasi marang pendapatan|Multiplikator P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Praxis Corp PRAX|AVXL: Multiplikator P/S|CBLL (ceribell.com) - Rasio rega marang pendapatan|PRTA (Prothena Corporation) - Multiplikator P/S|Kapitalisasi marang pendapatan alector.com (ALEC)|Rasio rega marang pendapatan Annexon, Inc. (ANNX)|OMER - Rega marang dodolan|Multiplikator P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rega marang dodolan|Voyager Therapeutics Inc - Multiplikator P/S|Neumora (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|TVGN - Koefisien rega marang pendapatan|ACOG (Alpha Cognition Inc) - Multiplikator P/S|Kapitalisasi marang pendapatan cogrx.com (CGTX)|Rasio rega marang pendapatan Inhibikase Therapeutics Inc (IKT)|Koefisien rega marang pendapatan Cassava Sciences|Multiplikator P/S ASRT (Assertio Holdings)|COYA - Kapitalisasi marang pendapatan|vistagen.com - Multiplikator P/S|OVID: Rasio rega marang pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang pendapatan|CervoMed Inc - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan PEPG (PepGen Inc)|Multiplikator P/S jupiterneurosciences.com (JUNS)|Rasio rega marang pendapatan Relmada Therapeutics, Inc. RLMD|GRCE: Rasio kapitalisasi marang pendapatan|AIFF - Rasio rega marang pendapatan|KLTO (anewmeds.com) - Rasio kapitalisasi marang pendapatan|NRSN (NeuroSense Therapeutics Ltd.) - Kapitalisasi marang pendapatan|revivapharma.com - Rasio kapitalisasi pasar marang pendapatan|MTVA (metaviatx.com) - Multiplikator P/S|NRXS: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S HSDT|PASG - Rega marang dodolan|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV: Rasio kapitalisasi marang pendapatan|ATHA: Kapitalisasi marang pendapatan|Addex Therapeutics Ltd - Kapitalisasi marang volume dodolan|Alzamend Neuro, Inc. (ALZN) - Rasio rega marang pendapatan|CYCN (Cyclerion Therapeutics Inc.) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan PTIX|KTTA: Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan CRGT (Cortigent Medical)|ATXI (Avenue Therapeutics, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Brainstorm Cell Therapeutics, Inc. BCLI|Rasio kapitalisasi pasar marang pendapatan CARA|chromocell.com - Multiplikator P/S|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|Rega marang dodolan Longboard Pharmaceuticals, Inc. (LBPH)|Rasio rega marang pendapatan Marinus Pharmaceuticals, Inc.|NKGN: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NRBO|SAGE: Rasio rega marang dodolan|Synaptogenix Inc. - Kapitalisasi marang pendapatan|Kapitalisasi marang volume dodolan TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - Multiplikator P/S|Anew Medical (WENA) - Kapitalisasi marang pendapatan|CERE (Cerevel Corp) - Kapitalisasi marang pendapatan
